FAF
SRPT icon

Första AP-fonden’s Sarepta Therapeutics SRPT Stock Holding History

Första AP-fonden’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-9,700
Closed -$1.55M – 544
2020
Q2 		$1.55M Buy
+9,700
New +$1.32M 0.04% 435

Other funds holding SRPT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Första AP-fonden's SRPT Position: Q3 2020 in Review

Första AP-fonden sold out of Sarepta Therapeutics (SRPT) in Q3 2020, closing a stake of 9,700 shares — an estimated $1.55M sold.

Första AP-fonden first reported a position in SRPT in Q2 2020 and held it in 1 quarter. The position peaked at $1.55M in Q2 2020. 403 funds tracked by Wall St. Rank hold SRPT as of Q3 2020.

  • Första AP-fonden reported no remaining Sarepta Therapeutics position as of Q3 2020 after selling out during the quarter.
  • Första AP-fonden sold 9,700 Sarepta Therapeutics shares in Q3 2020, an estimated $1.55M.
  • Första AP-fonden first reported a position in Sarepta Therapeutics in Q2 2020 and held it in 1 quarter.
  • Första AP-fonden's Sarepta Therapeutics position peaked at $1.55M in Q2 2020.
  • 403 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q3 2020.

Based on Första AP-fonden's 13F filing for Q3 2020, filed 22 Oct 2020.